Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic ...

Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 11.2% of Oncternal Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Vertex ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%.

Suzetrigine is under clinical development by Vertex Pharmaceuticals and currently in Phase III for Diabetic Peripheral Neuropathy. According to GlobalData, Phase III drugs for Diabetic Peripheral ...

Suzetrigine is under clinical development by Vertex Pharmaceuticals and currently in Pre-Registration for Post-Operative Pain. According to GlobalData, Pre-Registration drugs for Post-Operative Pain ...

Zoom is a video conferencing app, geared towards business usage. It was founded in 2011 by Eric Yuan, and launched in January 2013. While gathering considerable popularity and coming to run profitably ...

Recursion Pharmaceuticals has a flashy drug development platform. It has a lot to prove about whether that platform's use of AI is helpful. Some power players have backed it with significant ...